Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;8(Suppl 2):S163-S171.
doi: 10.21037/tlcr.2019.08.12.

What is the optimal radiotherapy utilization rate for lung cancer?-a systematic review

Affiliations
Review

What is the optimal radiotherapy utilization rate for lung cancer?-a systematic review

Wei Liu et al. Transl Lung Cancer Res. 2019 Sep.

Abstract

Lung cancer is a major cause of morbidity and mortality globally. Although radiotherapy (RT) may be beneficial in the radical and/or palliative management of many lung cancer patients, it is underutilized worldwide. Population-level development of RT resources requires estimates of optimal radiotherapy utilization rates (ORUR) and actual radiotherapy utilization rate (ARUR). A systematic review of PubMed database for English-language articles from January 2009 to January 2019 was performed. Keywords included utilization, underutilization, demand, epidemiologic, benchmark, RT and cancer. Data abstracted included: study population, diagnosis, stage, year of diagnosis, timing of RT, intent of RT, ARUR, and ORUR. Eligible studies provided ARUR or ORUR for lung cancer, small cell lung cancer (SCLC), or non-small cell lung cancer (NSCLC). Included ARUR were based on at least 1,000 patients who were diagnosed or treated in 2009 or later. Included ORUR were based on evidence review or ARUR in 2009 or later. The initial search strategy yielded 1,627 unique abstracts. After review, 105 articles were determined appropriate for full-text review. From these, a final set of 21 articles met all inclusion criteria. In eight papers, ORUR was estimated. Estimated lifetime ORUR ranged from 61% to 82%. Methods for estimation included the evidence-based guideline model, Malthus model, and criterion-based benchmarking (CBB) model. The majority of estimates (6/8) used the evidence-based guideline model. Fifteen papers provided ARUR on lung cancer, inclusive of SCLC and NSCLC. ARUR within 9 months to 1 year of diagnosis ranged from 39% to 46%. Lifetime ARUR was an estimated 52% in Ontario, Canada. Palliative intent ARUR ranged from 12% in Central Poland to 46% in Ontario, Canada. RT is underutilized for lung cancer globally, and there is wide geographical variation in the level of underutilization.

Keywords: Lung neoplasms; global health; radiotherapy (RT); systematic review.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. Louie has received honoraria from Varian Medical Systems Inc. and AstraZeneca. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flow chart of the article search strategy and systematic review process according to PRISMA guidelines. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; ARUR, actual radiotherapy utilization rate; ORUR, optimal radiotherapy utilization rate.

Similar articles

Cited by

References

    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. 10.3322/caac.21492 - DOI - PubMed
    1. NCCN Guidelines Version 5. Non-Small Cell Lung Cancer [Internet] 2019 [cited 2019 Aug 3]. Available online: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
    1. NCCN Guidelines Version 1 2019 Small Cell Lung Cancer [Internet] 2019 [cited 2019 Aug 3]. Available online: https://www.nccn.org/professionals/physician_gls/pdf/sclc_blocks.pdf
    1. Früh M, De Ruysscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24:vi99-105. 10.1093/annonc/mdt178 - DOI - PubMed
    1. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28:iv1-21. 10.1093/annonc/mdx222 - DOI - PubMed